NASDAQ
COAG
Last Price
US $36.73
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Hemab Therapeutics Holdings, Inc. Common Stock cash flow to debt ratio of -5.04K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio development.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
Hemab Therapeutics Holdings, Inc. Common Stock has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Hemab Therapeutics Holdings, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Decreasing performance - ROA.
Hemab Therapeutics Holdings, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Hemab Therapeutics Holdings, Inc. Common Stock's return on equity of 36.18%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Hemab Therapeutics Holdings, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Hemab Therapeutics Holdings, Inc. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Hemab Therapeutics Holdings, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Hemab Therapeutics Holdings, Inc. Common Stock has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Decreasing performance - Healthy revenue growth.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Decreasing performance - ROIC.
ROIC -37.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.
Decreasing performance - Revenue consistency.
Hemab Therapeutics Holdings, Inc. Common Stock had revenue growth in only 0.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Hemab Therapeutics Holdings, Inc. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Hemab Therapeutics Holdings, Inc. Common Stock has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Hemab Therapeutics Holdings, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Hemab Therapeutics Holdings, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Hemab Therapeutics Holdings, Inc. Common Stock has an EV/EBITDA ratio of 0.31x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Hemab Therapeutics Holdings, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Hemab Therapeutics Holdings, Inc. Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Hemab Therapeutics Holdings, Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
36.18%
Return on equity
ROIC: -37.82%
Valuation History
-13.9X
Price to Earnings
EV/EBITDA: 0.31X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $36.73
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.